Introduction
What treatments are used for Sjogren syndrome? Management usually combines symptom-directed therapy for dry eyes and dry mouth with, in selected cases, treatments that suppress immune activity and reduce inflammation in the salivary glands, lacrimal glands, joints, skin, lungs, kidneys, or nervous system. Sjogren syndrome is an autoimmune disease in which immune cells attack and inflame moisture-producing glands, especially the salivary and tear glands, so treatment is designed both to relieve dryness and to modify the immune process that damages these tissues.
The overall strategy depends on which organs are involved and how active the immune process is. Some therapies mainly replace lost secretions or improve surface lubrication, while others aim to reduce lymphocytic infiltration, preserve glandular function, and limit systemic injury. In practice, treatment is layered: local measures address the consequences of gland dysfunction, and systemic therapies are reserved for more extensive or inflammatory disease.
Understanding the Treatment Goals
The central goals of treatment are to reduce the symptoms caused by reduced gland output, prevent complications of chronic dryness, and control immune-mediated inflammation before it causes irreversible tissue injury. In the eyes, reduced tear production leaves the corneal surface exposed to friction and microtrauma; in the mouth, inadequate saliva impairs swallowing, speech, digestion, and the natural antimicrobial defenses that suppress dental decay and oral infection. Treatment therefore tries to replace the missing fluid functions and reduce secondary damage to mucosal surfaces.
A second goal is to address the underlying biology of the disease. Sjogren syndrome is characterized by autoimmune activation, including B-cell and T-cell driven inflammation, cytokine production, and in some patients systemic autoantibody activity. When disease extends beyond the glands, treatment may be used to suppress immune pathways that are contributing to arthritis, vasculitis, lung inflammation, neuropathy, renal tubular disease, or other organ involvement. The choice of treatment reflects whether the dominant problem is gland dysfunction alone or a broader inflammatory process.
Another treatment goal is prevention of progression and complications. Chronic inflammation can gradually destroy glandular tissue, while persistent dryness can lead to corneal injury, rampant dental caries, oral candidiasis, dysphagia, and impaired quality of life. In some patients, long-standing immune stimulation is also associated with an increased risk of lymphoma. Treatment and follow-up are therefore directed not only at symptoms but also at long-term surveillance for tissue damage and complications.
Common Medical Treatments
For dry eyes, the most common treatments are artificial tears, lubricating gels, and ointments. These products do not alter the autoimmune process, but they replace the water and mucin functions of the tear film, reducing evaporation and mechanical friction on the ocular surface. By maintaining a more stable tear layer, they protect the corneal epithelium from desiccation and inflammatory injury. Preservative-free formulations are often used when frequent dosing is needed, because some preservatives can irritate an already inflamed ocular surface.
Topical anti-inflammatory eye treatments are used when tear film instability is driven by active ocular surface inflammation. Cyclosporine eye drops reduce T-cell activation and cytokine signaling on the ocular surface, which can lessen inflammation in the lacrimal functional unit and improve tear production in some patients. Lifitegrast interrupts the interaction between lymphocytes and ocular surface adhesion molecules, reducing inflammatory cell recruitment and the cycle of surface irritation. These therapies aim to modify the local immune environment rather than simply lubricate the eye.
For dry mouth, treatment commonly includes saliva substitutes and saliva-stimulating agents. Saliva substitutes provide temporary lubrication and help compensate for the loss of fluid buffering, while stimulating agents such as pilocarpine and cevimeline act on muscarinic receptors to increase exocrine gland secretion. Their effect depends on residual gland tissue that can still respond to cholinergic stimulation. By increasing salivary flow, these drugs improve oral moisture, reduce swallowing difficulty, and help restore the cleansing and buffering functions that saliva normally provides.
When there is evidence of more active systemic disease, hydroxychloroquine is commonly used. This drug influences antigen processing and toll-like receptor signaling and can reduce some inflammatory symptoms such as arthralgia, fatigue, and mild constitutional complaints. Its effect is immunomodulatory rather than strongly immunosuppressive, so it is often used when the disease is not immediately organ-threatening. It is less effective for severe glandular destruction because it does not reverse established tissue loss.
Nonsteroidal anti-inflammatory drugs may be used for musculoskeletal pain related to inflammatory joint involvement. They inhibit cyclooxygenase enzymes and reduce prostaglandin-mediated pain and inflammation, but they do not change the autoimmune basis of the syndrome. Their use reflects symptom control rather than disease modification.
For more severe or organ-threatening disease, clinicians may use systemic corticosteroids and other immunosuppressive or biologic therapies. Corticosteroids suppress multiple inflammatory pathways, including cytokine production, leukocyte migration, and antigen-driven immune activation. They can rapidly reduce inflammation in affected tissues such as lungs, kidneys, nerves, or blood vessels. Because their effect is broad and not disease-specific, they are generally reserved for significant inflammatory activity or used temporarily while other therapies take effect.
Other systemic immunosuppressive agents, such as methotrexate, azathioprine, mycophenolate mofetil, or rituximab, may be selected for particular patterns of disease. Methotrexate and azathioprine reduce lymphocyte proliferation and inflammatory signaling. Mycophenolate interferes with lymphocyte nucleotide synthesis, limiting immune-cell expansion. Rituximab targets CD20-positive B cells, reducing a cell population that contributes to autoantibody production and antigen presentation. These drugs are generally used when the disease extends beyond dryness alone or when inflammatory activity persists despite simpler measures.
Procedures or Interventions
Several interventions are used when local measures are insufficient. For eye disease, punctal occlusion may be performed to reduce tear drainage. By blocking the puncta, natural tears and applied lubricants remain longer on the eye surface, increasing the effective tear reservoir. This procedure does not increase tear production, but it improves tear retention and reduces surface evaporation, which can be useful in patients whose main problem is tear loss rather than excess tear evaporation.
In selected patients, ophthalmologic procedures may also be used to protect the cornea if dryness has caused significant surface injury. These interventions work by reducing exposure, improving tear distribution, or shielding damaged epithelium from ongoing friction. Their role is structural and protective: they aim to prevent ulceration, scarring, and chronic pain by improving the ocular surface environment.
Dental and oral interventions are also central in Sjogren syndrome. Frequent professional dental care, fluoride application, and management of oral infections are used because reduced saliva impairs remineralization and removes the buffering effect that normally limits acid damage. Some patients may require treatment of salivary gland enlargement, evaluation of persistent gland asymmetry, or biopsy when lymphoma or another pathology is suspected. Biopsy is not a treatment for dryness itself, but it helps clarify whether the gland tissue is showing characteristic lymphocytic infiltration or a more serious complication.
Supportive or Long-Term Management Approaches
Long-term management relies on ongoing control of the consequences of gland dysfunction and periodic reassessment of disease activity. Because gland damage is chronic, treatments often need to be continued or adjusted over time. The physiologic logic is straightforward: when saliva and tears remain insufficient, the downstream effects on the eye, mouth, and upper airway persist unless local replacement or stimulation is maintained.
Monitoring is part of treatment because Sjogren syndrome can evolve slowly and affect multiple organ systems. Follow-up evaluations assess tear production, oral health, joint symptoms, blood counts, inflammatory markers, and organ-specific function when needed. This monitoring helps determine whether the disease remains limited to exocrine glands or has progressed to systemic involvement, which would shift treatment toward immunomodulatory or immunosuppressive therapy.
Supportive care also includes managing secondary consequences of dryness. Reduced saliva changes the oral microbial environment, making cavities, fungal overgrowth, and periodontal disease more likely. Reduced tears increase the risk of ocular surface inflammation and corneal injury. Long-term management therefore aims to maintain the physiological roles that secretions normally serve: lubrication, buffering, antimicrobial protection, and tissue repair.
Factors That Influence Treatment Choices
Treatment varies according to the severity and distribution of disease. A patient with isolated dryness and no systemic inflammation may need only local ocular and oral therapy, whereas a patient with arthritis, neuropathy, interstitial lung disease, renal involvement, or vasculitis may need systemic therapy to suppress active immune injury. The more the disease behaves like a multisystem inflammatory disorder, the more likely treatment will include immune-modifying drugs.
The stage of gland damage also matters. If salivary or lacrimal tissue still retains some secretory function, muscarinic agonists may improve output by stimulating remaining acinar cells. If tissue destruction is advanced, stimulation has less benefit because there are fewer functioning cells left to respond. Similarly, anti-inflammatory eye drops may help when inflammation is still active, but they cannot fully restore glands that have been replaced by fibrosis or lymphoid infiltrates.
Age, general health, and related conditions influence choice because they affect tolerance and risk. Older patients or those with cardiovascular disease, glaucoma, liver disease, kidney disease, or medication sensitivity may not tolerate certain drugs as well. Other autoimmune diseases, such as rheumatoid arthritis or systemic lupus erythematosus, may also shape treatment because they change the pattern of immune activity and may require therapies that address more than Sjogren syndrome alone.
Previous response to treatment is another determinant. Some patients improve with lubricants and cholinergic stimulation, while others require escalation to systemic immunosuppression. The pattern of response helps distinguish primarily functional gland impairment from ongoing inflammatory injury, and that distinction drives whether therapy remains local or becomes systemic.
Potential Risks or Limitations of Treatment
Local lubricants and saliva substitutes are generally safe, but they do not reverse the autoimmune process or repair glandular destruction. Their main limitation is that they replace function temporarily rather than restoring normal physiology. They may also provide incomplete relief when secretion loss is severe.
Muscarinic agonists can increase secretion, but their effect is limited to patients with residual gland function. Because they stimulate cholinergic receptors throughout the body, they can also cause sweating, abdominal cramping, flushing, urinary frequency, or bradycardia. These effects arise from the same parasympathetic activation that drives gland stimulation.
Topical and systemic anti-inflammatory therapies carry their own risks. Cyclosporine or lifitegrast can cause local burning or irritation because they alter the inflammatory balance on already sensitive ocular surfaces. Corticosteroids can improve inflammation quickly, but prolonged use can lead to metabolic effects, infection risk, bone loss, hypertension, cataracts, or glaucoma. These complications reflect the broad biologic role of glucocorticoids in immune regulation and tissue metabolism.
Systemic immunosuppressive drugs and biologics may increase susceptibility to infection, alter blood counts, affect liver or kidney function, or cause infusion reactions, depending on the agent. Their use requires a balance between reducing immune-mediated tissue damage and preserving host defense. Another limitation is that none of these therapies reliably cure Sjogren syndrome or fully restore normal gland architecture once substantial destruction has occurred. Treatment often improves symptoms and reduces inflammatory activity, but glandular function may remain chronically reduced.
Conclusion
Sjogren syndrome is treated through a combination of local symptom control and, when necessary, systemic immune modulation. Dry eyes and dry mouth are managed with lubricants, saliva substitutes, and agents that stimulate the remaining gland tissue, while inflammatory activity may be treated with topical anti-inflammatory drugs, hydroxychloroquine, corticosteroids, or other immunosuppressive and biologic therapies. Procedures such as punctal occlusion or targeted oral and ophthalmologic interventions are used when structural protection or tear retention is needed.
The unifying principle of treatment is biological: therapies either replace the lost functions of damaged glands, stimulate residual secretion, or reduce the autoimmune inflammation that drives tissue injury. Because Sjogren syndrome ranges from isolated dryness to systemic inflammatory disease, treatment is individualized according to severity, organ involvement, and response over time. The most effective management strategies are those that match the therapy to the specific physiological defect being addressed.